Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Liver Fibrosis & Organ-Specific Pathology
Are you currently facing challenges translating novel cell therapies for refractory chronic liver disease, highly variable rodent data, and stringent regulatory demands for human-allied models? Our specialized NHP Disease Models help you streamline preclinical assessment and de-risk IND submissions by leveraging validated fibrosis models and high-fidelity organ engraftment assays.
NHP De-risk Your Cell Therapy Pipeline with Translational Confidence!
Translational studies require models that accurately reflect human disease progression and immune response. NHP models provide essential, human-allied data for verifying the safety and efficacy of complex iPSC-derived therapies and whole-organ constructs.
Overview of NHP Applications
What Are Our Research Areas?
Refractory chronic liver failure, primarily caused by liver cirrhosis, remains a major global health crisis, with orthotopic liver transplantation being the only definitive curative treatment. Given the profound shortage of donor organs, the field of regenerative hepatology is rapidly pivoting toward developing cell-based and bio-engineered solutions. This research area focuses on utilizing Hepatocyte-like Cells derived from human Induced Pluripotent Stem Cells as a cell source to either mitigate the severity of liver failure, or to serve as the building blocks for full-scale bio-organs. Successful clinical translation demands rigorous preclinical validation in large animal models that accurately replicate the complex pathology of human cirrhosis.
Why Choose Us?
Non-Human Primates (NHPs) offer an essential, non-negotiable bridge between small animal studies and human clinical trials, particularly for complex, organ-specific regenerative therapies.
- Genetic and Immunological Fidelity: NHPs share close homology to the human Major Histocompatibility Complex (MHC)/Human Leukocyte Antigen (HLA) system, allowing for the most accurate assessment of the immune response, allogeneic rejection, and xenogeneic complications associated with cell transplantation.
- Physiological and Anatomical Similarity: NHPs possess a hepatic micro-architecture, portal circulation system, and anatomical scale that closely mirrors humans, enabling the use of clinically relevant delivery methods and accurate assessment of biomaterial scaffolding integration.
- Longitudinal Monitoring Capability: The long lifespan and manageable nature of NHPs allow for extended, long-term monitoring of therapeutic effects, including tracking fibrosis reversal, cell survival, and potential long-term adverse events, which is critical for chronic diseases.
Distributed under Unsplash License, from Unsplash.
Key Applications
Creative Biolabs leverages our NHP models to provide definitive data for complex studies:
- Model Validation and Optimization for Cell Therapy: We establish and refine chronic liver disease models that accurately reproduce the hostility of the fibrotic microenvironment. These validated models are essential for determining the minimum effective dose and appropriate delivery route.
- Immunogenicity and Systemic Safety Screening: We provide rigorous evaluation of the host immune response to transplanted cells, including the assessment of rejection, inflammation, and T-cell activation in response to allogeneic or xenogeneic cellular products. This data is crucial for selecting and optimizing the necessary immunosuppressive regimen.
- Organ-Specific Biomarker and Endpoints Establishment: We work with clients to identify and validate surrogate biomarkers that correlate with human clinical outcomes and use advanced imaging to monitor portal hypertension and fibrosis progression over time.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs offers a suite of integrated services designed to support every phase of regenerative hepatology development.
| Service Capability | Corresponding Application Area |
| Fibrosis Model Development | Preclinical efficacy testing of anti-fibrotic drugs and hiPSC-HLC cell therapies. |
| Cell Therapy Models (iPSC-derived) | Evaluating the therapeutic potential, integration, and functional viability of cell products in a chronic disease setting. |
| Advanced Therapy Safety (Cell Therapy) | Assessing the local and systemic safety profile and immune complications of novel cell-based therapeutics, including tumorigenicity risk. |
| Tissue IHC/IF & In Situ Hybridization | Detailed confirmation of donor cell survival, differentiation status, and pathological changes in the liver tissue post-engraftment. |
Translational Impact
Leveraging Creative Biolabs' NHP platform for liver fibrosis provides an immediate, high-impact advantage to your translational pipeline. Our NHP models allow for the detection of cell product engraftment and assessment of immune responses in a large-animal model that closely mirrors human pathophysiology, generating the high-fidelity translational data often required by regulatory bodies for complex cell therapy IND submissions. This rigorous pre-clinical data is critical for achieving a more reliable early proof of concept and significantly reducing the risk of costly clinical failure. By understanding the true survival, function, and immunogenicity of your cell product in an NHP, you can optimize your therapeutic strategy before entering the clinic.
Frequently Asked Questions
Q: How do you track the survival and functional contribution of transplanted cell products?
A: We use a multi-modal approach. This includes transplanting cell products engineered with reporter genes for tissue immunofluorescence/histology tracking. Function is assessed via analysis of human-specific metabolites or protein products in NHP serum, offering a clear signal of therapeutic contribution.
Q: What immunosuppressive regimens are used to facilitate cell products engraftment in your NHP models?
A: We develop tailored immunosuppression protocols based on the specific needs of your cell product and target organ. This often involves clinically relevant agents, closely monitored for systemic toxicity to ensure the immune environment is conducive to engraftment while remaining translationally relevant.
Q: What is the typical turnaround time and data format for a long-term fibrosis and cell therapy study?
A: The duration of a study involving chronic disease induction, cell transplantation, and long-term follow-up typically ranges from 6 to 12 months. Data is delivered in comprehensive, regulatory-ready reports, including raw data, PK/PD modeling, detailed histopathology images, and integrated bioinformatics analysis.
Contact Us
Creative Biolabs provides specialized NHP models and integrated analytical services for the rigorous preclinical testing of iPSC-derived cell therapies and bio-engineered organs targeting complex liver pathology. Contact us now, for detailed scientific discussion, customized study designs, and prompt quotations, we deliver the translational data required to de-risk your program, move beyond rodent variability, and confidently transition to the clinic.